Apotex Upsized IPO Priced
Analysis based on 9 articles · First reported May 28, 2026 · Last updated Jun 10, 2026
The successful launch and pricing of Apotex's upsized IPO, raising over $1.3 billion, indicates strong investor confidence in the pharmaceutical sector and Apotex's growth prospects. This event directly impacts the Canadian financial markets by adding a significant new listing to the Toronto Stock Exchange and provides liquidity for existing shareholders like SK Capital Partners.
Apotex, a Canadian-based global health company, has successfully launched and priced its upsized initial public offering (IPO). The company initially filed a preliminary prospectus on May 28, 2026, and officially launched its IPO on June 1, 2026, with an expected gross proceeds of approximately $1 billion. The offering was subsequently upsized on June 8, 2026, to approximately $1.3 billion. On June 9, 2026, Apotex announced the pricing of its IPO at $24.00 per common share, resulting in gross proceeds of $1,300,000,080. The offering includes a treasury offering by Apotex, raising $849,999,984 for the company, and a secondary offering by certain shareholders, including SK Capital Partners, generating $450,000,096. The common shares are expected to begin trading on the Toronto Stock Exchange under the symbol 'APTX' on June 10, 2026, with conditional approval already granted by the exchange. A syndicate of underwriters, including Royal Bank of Canada — RBC Capital Markets, Meritz Securities, and Scotiabank, is leading the offering.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard